We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Med BioGene Welcomes Renowned Expert to Lymphoma Collaboration

Med BioGene Welcomes Renowned Expert to Lymphoma Collaboration

Med BioGene Welcomes Renowned Expert to Lymphoma Collaboration

Med BioGene Welcomes Renowned Expert to Lymphoma Collaboration

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Med BioGene Welcomes Renowned Expert to Lymphoma Collaboration"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Med BioGene Inc. has welcomed Sandeep S. Dave, M.D. of Duke University to its lymphoma collaboration. MBI and Duke entered into a research collaboration and option agreement in March 2007.

Dr. Dave came to Duke this summer as an Assistant Professor in the Institute for Genome Sciences and Policy and in the Department of Medicine's Division of Medical Oncology.

Prior to joining Duke, Dr. Dave was a postdoctoral fellow at the laboratory of Louis Staudt at the National Cancer Institute. At the Staudt laboratory, Dr. Dave was involved in translational research aimed at using gene expression profiling to understand the role of differentially activated molecular pathways in non-Hodgkin lymphoma.

Dr. Dave has authored numerous articles in peer reviewed journals, including two as lead author in the New England Journal of Medicine, "Molecular Diagnosis of Burkitt's lymphoma" and "Prediction of Survival in Follicular Lymphoma based on Molecular Features of Tumor-Infiltrating Immune Cells".

Dr. Dave attended graduate school, medical school and completed his residency in internal medicine at Northwestern University. He completed a fellowship in hematology and medical oncology at the National Institutes of Health.

"I am very excited to work with Med BioGene and to expand upon the work that I undertook at the National Cancer Institute. Gene expression profiling has demonstrated that lymphoma types that were previously regarded as homogenous can harbor subgroups that are dramatically different in their biology and responses to therapy. Such studies could form the basis for risk stratification and tailored therapies that are most likely to benefit molecularly defined subgroups of patients," noted Dr. Dave.